ZyVersa Therapeutics Appoints Three New Board Members

New appointments bring expertise and proven leadership to ZyVersa to support advancement and development of VAR 200 for renal disease, and IC 100 for inflammatory diseases WESTON, Fla., Jan. 5, 2023 -- (Healthcare Sales & Marketing Network) -- ZyVersa ... Biopharmaceuticals, Personnel ZyVersa Therapeutics, glomerulosclerosis, Alport Syndrome, Kidney Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news